MultiStem: Additional Phase I data

Additional data from an open-label, dose-escalation Phase I trial in 36 patients showed that a single injection of the highest dose of IV MultiStem given following allogeneic hematopoietic stem cell transplant (HSCT) led to a 100-day cumulative incidence of moderate to severe

Read the full 429 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE